Merck KGaA’s Strategic Acquisition of SpringWorks Therapeutics Gains Momentum

Six months after finalizing its acquisition, Merck KGaA is hitting significant milestones in its integration of SpringWorks Therapeutics. The operational focus has now shifted decisively toward realizing synergies and launching new oncology treatments, following the delisting of SpringWorks’ shares from the Nasdaq last summer.

• Acquisition Cost: The transaction was valued at approximately $3.9 billion, equating to $47 per share.
• Strategic Focus: The deal expands Merck’s portfolio in rare cancers with the drugs OGSIVEO and EZMEKLY.
• Financial Target: Management anticipates the acquisition will begin contributing positively to adjusted earnings per share (EPS) by 2027.

Strengthening the Oncology Pipeline

The purchase granted Merck access to specialized therapies that have already cleared major regulatory hurdles. OGSIVEO (nirogacestat), a treatment for desmoid tumors, received approval from the European Commission in August of last year, following prior clearance from the U.S. FDA. This asset is complemented by EZMEKLY, which has held conditional EU marketing authorization since July 2025 for specific tumors in both pediatric and adult patients.

Recent clinical data supports the long-term efficacy of these treatments. In October last year, positive long-term results from the Phase 3 DeFi trial were released, reinforcing the safety profile and effectiveness of OGSIVEO. A key question for the Darmstadt-based company is when this multi-billion dollar investment will fully mature into stable market share.

Should investors sell immediately? Or is it worth buying SpringWorks Therapeutics?

Operational Efficiencies and Forward Guidance

Merck is leveraging the integration process to optimize its organizational structure. Last month, its North American healthcare business, EMD Serono, streamlined its research operations. This move, coming shortly after the SpringWorks deal closed, is designed to consolidate R&D resources within the Healthcare segment more efficiently.

Financial projections are underpinned by solid preliminary performance. OGSIVEO generated net sales of around $172 million for the full year 2024. Even prior to the acquisition, SpringWorks was forecast to reach profitability in the first half of 2026.

Through this and other strategic purchases, Merck KGaA aims to build a more resilient and growing Healthcare business. According to current planning, a material positive contribution to adjusted earnings per share is targeted for the 2027 fiscal year. This is expected to coincide with the full integration of sales infrastructures and deeper market penetration for the newly acquired medications.